Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the efficacy and safety of empagliflozin versus placebo as add-on therapy in patients with type 2 diabetes and inadequate glycemic control with linagliptin and metformin.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Diabetes Care

Title: Diabetes care

Publisher: American Diabetes Association

ISSN (Electronic): 1935-5548

ISSN (Print): 0149-5992

Publication date (Electronic): Feb 2017

Volume: 40

Issue: 2

Affiliations

[1 ] Haukeland University Hospital, Bergen, Norway eirik.softeland.med@helse-bergen.no.

[2 ] Ruhr-Universität Bochum, Bochum, Germany.

[3 ] Boehringer Ingelheim Norway KS, Asker, Norway.

[4 ] Boehringer Ingelheim Ltd., Bracknell, Berkshire, U.K.

[5 ] Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Article

Publisher Item ID: dc16-1347

DOI: 10.2337/dc16-1347

PubMed ID: 27913576

SO-VID: 59a99822-2b1e-4ab2-88e3-c9ada885241f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 50

See all cited by